The Federal Antimonopoly Service (FAS) considered that the pharmaceutical company Axelpharm had violated the law on the protection of competition, according to the department’s Telegram channel.
Author:
https://rb.ru/author/ntihonov/
Subscribe to RB.RU on Telegram
“The organization is ordered to transfer more than 513 million rubles of illegally obtained income to the budget,” the antimonopoly service said in a statement.
The pharmaceutical company, according to the Federal Antimonopoly Service, put into circulation a generic version of the antitumor drug Axitinib, the original of which is protected by patent until June 2025.
The department considered that “the entry of a generic drug onto the market before the patent of the original drug expires is unfair competition” both in relation to the suppliers of the original drug and in relation to other pharmaceutical companies that have registered their generics and are waiting that the patent expires for its legal circulation.
As reported by Rossiyskaya Gazeta, Axelpharm participated in several regional tenders for the purchase of a generic version of the antitumor drug Axitinib. The patent holder (Aguron Pharmaceuticals Elastics) and the importer (Pfizer Innovations LLC) reported unfair actions by a competitor to FAS.
In mid-October, the FAS ordered MTS to transfer 3 billion rubles of “illegally earned income” to the federal budget and reduce the cost of communication services for more than 30 million subscribers, after the operator increased its tariffs. in May.
Author:
Nikolai Tikhonov
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
